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Retinoids and hyperostosis
Sir, The ar by van Dooren-Greebe et ft/.1 requires
clarification. The authors indicate that 77 of their subjects 
were treated with synthetic retinoids for psoriasis but give no 
indication how many of these subjects also had evidence of 
psoriatic arthritis or psoriatic spondylitis. Nor is it clear how  
many of the patients having baseline X-rays had psoriasis. 
This is important for two reasons;
1 If none of the 77 patients with
s. it isarthropathy or spon 
excluded a population of patients
2 The rt äes of psoriatic s
lble from DISH and retinoid-induced
was ‘unaware of details from
patients records’, there is the possibility 
spinal lì
of
Perhaps the authors could look again at their data with 
particular reference to psoriatic arthritis and spondylitis.
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Sir, We would like to reply to the letter of Drs I 
Cheesbrough, concerning our recent article.
tc
In the present retrospective w e on
relationship of the duration of oral retinoid treatment and 
the prevalence of spinal abnormalities. We could not
strale such a relationship. Not a single pi was
from tre a t m e n t beca u s e
al abnormalities. Patients with psoriatic s or
itis were not excluded from retinoid treatment.
As study had a retrospective and
>e of the fact that baseline X-rays were not available in 
all patients, we were not able to make a subdivision in patients
with and without (pre-existing) spinal
'm í
As we stated in the discussion part of this communication 
we agree with Drs Cheesbrough and Helliwell that it might 
possible that a certain group of patients, for example
patients with psoriatic arthritis or psoriatic spondylitis, might
be at high-risk for the 
ìbnormalities. Further¥C
of retinoid-induced skeletal
be on
investigations s
high-risk patient
groups in
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Is methotrexate liver toxicity modest worldwide?
Sir, I read with interest the article of Dr M.J.Boffa et a l  on
( MTX ) liver in iasis.1 MTX has
been neglected for years in Italy because of an overemphasized 
fear of liver toxicity. The reappraisal is therefore welcome. 
However, how can a study on liver toxicity be performed 
without any evaluation of previous hepatitis C virus (HCV)
As far as I am aware, no studies on MTX liver toxicity have
n i a interaction HCV
infection. HCV infected patients may have neither symptoms 
nor elevation of liver enzymes yet still have chronic active
atitis. Tra nsam i n ases
which may pass unnoticed. In such patients, introduction of a 
toxic and immunosuppressive drug like MTX may reactivate 
the virus and increase liver toxicity.
Actually, as HCV infection in Dr Boffa’s geographical area 
affects only 0-04% of blood donors,2 none of his p 
likely to be HCV positive. However, lack of information 
HCV status, does not permit optimistic conclusions about MT>
safety that may not be shared in c 
prevalence than the U.K.5
ics higher HCV
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